11 Mar 2020 --- The US Food and Drug Administration (FDA) will officially reopen the public comment window on cannabis and cannabidiol (CBD) products, “extending it indefinitely.” Although the extended comment period is to collect more scientific data on cannabis products across the supply chain, US-based Natural Products Association (NPA) has pegged the move as a “huge and surprising step backward.” Moreover, it accuses the FDA of “risking a public health crisis by delaying necessary regulatory action on CBD.” Supply chain transparency and product safety are of increasing significance as cannabis-derived NPD thrives in the blossoming CBD market.
